These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26773546)

  • 21. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
    Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
    J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality Rates in Patients With Chronic Hepatitis C and Cirrhosis Compared With the General Population: A Danish Cohort Study.
    Hallager S; Brehm Christensen P; Ladelund S; Rye Clausen M; Lund Laursen A; Møller A; Schlicthting P; Galmstrup Madsen L; Gerstoft J; Lunding S; Elmegaard Grønbæk K; Bygum Krarup H; Weis N
    J Infect Dis; 2017 Jan; 215(2):192-201. PubMed ID: 27803168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan.
    McDonald SA; Hutchinson SJ; Innes HA; Allen S; Bramley P; Bhattacharyya D; Carman W; Dillon JF; Fox R; Fraser A; Goldberg DJ; Kennedy N; Mills PR; Morris J; Stanley AJ; Wilks D; Hayes PC
    J Viral Hepat; 2014 May; 21(5):366-76. PubMed ID: 24716639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
    Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
    J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
    Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
    J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burden of Hepatitis C in Iran Between 1990 and 2010: findings from the Global Burden of Disease Study 2010.
    Mohaghegh Shalmani H; Noori A; Shokoohi M; Khajavi A; Darvishi M; Delavari A; Jamshidi HR; Naderimagham S
    Arch Iran Med; 2015 Aug; 18(8):508-14. PubMed ID: 26265519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patients.
    Nakagawa H; Fujiwara N; Tateishi R; Arano T; Nakagomi R; Kondo M; Minami T; Sato M; Uchino K; Enooku K; Asaoka Y; Kondo Y; Shiina S; Yoshida H; Koike K
    J Gastroenterol Hepatol; 2015 Feb; 30(2):379-88. PubMed ID: 25168107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease burden of chronic hepatitis C among immigrants in Canada.
    Chen W; Krahn M
    J Viral Hepat; 2015 Dec; 22(12):1043-54. PubMed ID: 26110922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
    Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
    Innes H; Goldberg D; Dusheiko G; Hayes P; Mills PR; Dillon JF; Aspinall E; Barclay ST; Hutchinson SJ
    J Hepatol; 2014 Jun; 60(6):1118-26. PubMed ID: 24509410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study.
    Hansen N; Obel N; Christensen PB; Krarup H; Laursen AL; Clausen MR; Lunding S; Møller A; Schlichting P; Kromann-Andersen H; Bukh J; Weis N;
    J Viral Hepat; 2009 Sep; 16(9):659-65. PubMed ID: 19486467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia.
    Mohanty A; Erqou S; McGinnis KA; Vanasse G; Freiberg MS; Sherman KE; Butt AA
    Clin Gastroenterol Hepatol; 2013 Jun; 11(6):741-7.e3. PubMed ID: 23376794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013).
    Klein MB; Rollet-Kurhajec KC; Moodie EE; Yaphe S; Tyndall M; Walmsley S; Gill J; Martel-Laferriere V; Cooper C;
    AIDS; 2014 Aug; 28(13):1957-65. PubMed ID: 25259703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013.
    Johnson NB; Hayes LD; Brown K; Hoo EC; Ethier KA;
    MMWR Suppl; 2014 Oct; 63(4):3-27. PubMed ID: 25356673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study.
    Bedogni G; Miglioli L; Masutti F; Ferri S; Castiglione A; Lenzi M; Crocè LS; Granito A; Tiribelli C; Bellentani S
    Am J Gastroenterol; 2008 Sep; 103(9):2248-53. PubMed ID: 18637095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
    Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ
    Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.
    Moucari R; Asselah T; Cazals-Hatem D; Voitot H; Boyer N; Ripault MP; Sobesky R; Martinot-Peignoux M; Maylin S; Nicolas-Chanoine MH; Paradis V; Vidaud M; Valla D; Bedossa P; Marcellin P
    Gastroenterology; 2008 Feb; 134(2):416-23. PubMed ID: 18164296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.